search
Company Information
USD
12.08
- (-0.5%)
NASDAQ:NRIX, NURIX THERAPEUTICS, INC.
Industry: Biotechnology
End of Day: 3 June 2025 GMT-4
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Address

1700 Owens Street
Suite 205

Classification

Sector

Healthcare

Industry Group

Biotechnology

Industry

Biotechnology

Key Executives

Dr. Arthur T. Sands, M.D.,PhD
CEO/Director/President
Ms. Julia P. Gregory
Director
Ms. Judith A. Reinsdorf, J.D.
Director
Mr. Paul M. Silva
Director
Dr. Lori Anne Kunkel, M.D.
Director
Dr. David L. Lacey, M.D.
Chairman of the Board/Director
Mr. Hans van Houte
CFO/Chief Accounting Officer
Mr. Edward C. Saltzman
Director
Dr. Gwenn Hansen, PhD
Chief Scientific Officer
Dr. Christine Ring, J.D.,PhD
General Counsel/Secretary

Ownership

Institution Holdings

BlackRock Inc
4,643,736 (9.498%)
Baker Bros Advisors LP
3,882,125 (7.940%)
Baker Bros. Advisors LP
3,882,125 (7.940%)
ARK Investment Management LLC
3,194,999 (6.535%)
Morgan Stanley - Brokerage Accounts
3,135,037 (6.412%)
Deep Track Capital, LP
2,997,830 (6.131%)
Redmile Group, LLC
2,848,827 (5.827%)
Wasatch Advisors Inc.
2,749,745 (5.624%)
Vanguard Group Inc
2,598,097 (5.314%)
T. Rowe Price Associates, Inc.
2,389,966 (4.888%)

Individual Holdings

Dr. Arthur T. Sands, M.D.,PhD
308,333 (0.885%)
Dr. Lori Anne Kunkel, M.D.
54,027 (0.155%)
Mr. Hans van Houte
68,333 (0.140%)
Dr. David L. Lacey, M.D.
33,333 (0.096%)
Dr. Gwenn Hansen, PhD
36,402 (0.075%)
Dr. Christine Ring, J.D.,PhD
17,427 (0.036%)

Funds Holdings

ARK Genomic Revolution
3,165,329 (6.474%)
ARK Genomic Revolution ETF
2,768,694 (5.663%)
US Small-Cap Growth II Equity Comp
1,322,383 (2.705%)
T. Rowe Price New Horizons Fund
1,322,383 (2.705%)
iShares Russell 2000 ETF
1,184,518 (2.423%)
Wasatch Ultra Growth Fund
965,610 (1.975%)
Wasatch Small Cap Value Fund
702,910 (1.438%)
Vanguard Institutional Extnd Mkt Idx Tr
677,671 (1.386%)
Candriam Global Equities Oncology
563,096 (1.152%)
Pictet - Biotech
511,284 (1.046%)

Details

Overview Company Info Key Ratios Income Balance Sheet Cash Flow
Make Smart Investment Choices